Evaluation of prognosis and nephrotoxicity in patients treated with colistin in intensive care unit. Issue 1 (1st January 2020)

• Record Type: Journal Article
• Authors: Gunay, Emrah; Kaya, Safak; Baysal, Birol; Yuksel, Enver; Arac, Esref
• Is Part Of: Renal failure. Volume 42:Issue 1(2020)
• Page Start: 704
• Page End: 709
• Publication Date: 2020-01-01
• Subjects: Acute kidney injury -- colistin -- intensive care unit -- mortality -- nephrotoxicity; Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.1080/0886022X.2020.1795878
• Languages: English
• ISSNs: 0886-022X

Abstract

Abstract: Introduction: Nephrotoxicity is the most important adverse effect of colistin therapy. We investigated the frequency of nephrotoxicity, risk factors related to nephrotoxicity, and its relationship with mortality in patients who received intravenous colistin in intensive care units (ICUs). Materials and methods: We retrospectively reviewed the data of patients who received intravenous colistin in ICUs between 2011 and 2017. Acute kidney injury (AKI) diagnosis and staging were made based on the Kidney Disease Improving Global Outcome criteria. Results: There were 149 patients included in the study with 61% being male. The mean age was 58.7 ± 20.3 years. AKI was detected in 96 (64.4%) patients. There were 25 patients with AKI stage 1 (16.8%) and 71 patients with AKI stage 2 or 3 (47.7%). Advanced age (65.0 vs. 47.4 years; p < .001), diabetes mellitus ( p < .001), heart failure ( p = .01), high APACHE II score (31.7 vs. 28.08, p = .019), and inotrope usage ( p = .01) were found as risk factors for AKI. The 14-day mortality rate was higher in the AKI group ( p = .027). Discussion: Higher AKI and mortality rates are observed in patients with diabetes, heart failure, advanced age and the hemodynamically impaired. However, it is a fact that there are no alternative therapies other than colistin in the treatment of multidrug-resistant Gram-negative bacterial infections. Therefore, the development of AKI in this patient group should not be considered a sufficient reason for discontinuing colistin treatment. Understanding the risk factors in this potential nephrotoxic treatment can provide a more careful patient follow-up.